Literature DB >> 16479721

Graft-versus-host disease in severe combined immunodeficiency/beige mice administered canine leukocytes.

Jeff L Caswell1, Julie A Yager.   

Abstract

This report describes the development and lesions of graft-versus-host disease (GVHD) in severe combined immunodeficiency/ beige (SCID/BG) mice after the administration of canine leukocytes. Intraperitoneal injections of 0.87 x 10(7) canine lymphocytes were given to each of 9 mice; 5 mice received no canine lymphocytes. Morphologic evidence of successful engraftment included peritoneal aggregates of lymphocytes and repopulation of spleen and lymph nodes by lymphocytes. Canine CD45R was expressed by 2.25% of peripheral blood leukocytes in the 1 mouse tested 65 d after engraftment but by none of the cells of a control mouse. Canine immunoglobulin G was detected in serum samples from 5 of the 6 tested mice given canine lymphocytes but none of the control mice. By 13 to 65 d after receiving canine lymphocytes, 5 of the 9 mice had died of GVHD or had been euthanized because of it; all the control mice remained healthy. Lesions of GVHD included hemolytic anemia, cholangiohepatitis, alveolitis, and disseminated intravascular coagulation. Serum from the donor dog and from all 15 randomly selected dogs caused agglutination of normal mouse erythrocytes, supporting a diagnosis of immune-mediated hemolytic anemia in the dog-mouse chimeras. All of the mouse serum tested contained murine immunoglobulin, and this "leakiness" may have contributed to the development of GVHD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16479721      PMCID: PMC1250235     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  22 in total

1.  Long-term xenogeneic chimeras. Full differentiation of rat T and B cells in SCID mice.

Authors:  C D Surh; J Sprent
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

2.  Hemagglutination and graft-versus-host disease in the severe combined immunodeficiency mouse lymphoproliferative disease model.

Authors:  S J Pirruccello; H Nakamine; K W Beisel; K L Kleveland; M Okano; Y Taguchi; J R Davis; M L Mahloch; D T Purtilo
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

3.  Biliary duct lesions following xenogeneic liver and peripheral blood lymphocyte grafts in SCID mice.

Authors:  J M Bestian; A Janin; I Zenner; D Zelus; F R Pruvot; J P Dessaint; A Capron
Journal:  Transplant Proc       Date:  1995-04       Impact factor: 1.066

4.  Demonstration of a splenic cytotoxic effector cell in mice of genotype SCID/SCID.BG/BG.

Authors:  J R MacDougall; B A Croy; C Chapeau; D A Clark
Journal:  Cell Immunol       Date:  1990-10-01       Impact factor: 4.868

Review 5.  Xenogeneic PBL-scid mice: their potential and current limitations.

Authors:  J D Greenwood
Journal:  Lab Anim Sci       Date:  1993-04

6.  Peritoneal sanctuary for human lymphopoiesis in SCID mice injected with human peripheral blood lymphocytes from Epstein-Barr virus-negative donors.

Authors:  G Hoffmann-Fezer; B Kranz; C Gall; S Thierfelder
Journal:  Eur J Immunol       Date:  1992-12       Impact factor: 5.532

7.  Characterization of hu-PBL-SCID mice with high human immunoglobulin serum levels and graft-versus-host disease.

Authors:  M A Duchosal; S A Eming; P J McConahey; F J Dixon
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

8.  A study on the engraftment and trafficking of bovine peripheral blood leukocytes in severe combined immunodeficient mice.

Authors:  J D Greenwood; B A Croy
Journal:  Vet Immunol Immunopathol       Date:  1993-09       Impact factor: 2.046

9.  Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis.

Authors:  P F Piguet; G E Grau; M A Collart; P Vassalli; Y Kapanci
Journal:  Lab Invest       Date:  1989-07       Impact factor: 5.662

10.  Generation of biliary lesions after transfer of human lymphocytes into severe combined immunodeficient (SCID) mice.

Authors:  S M Krams; K Dorshkind; M E Gershwin
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.